D

DBV Technologies SA

DBVT

0.95000
USD
0.0029
(0.31%)
مغلق
حجم التداول
41,033
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
68,312,264
أصول ذات صلة
B
BIIB
-2.500
(-1.17%)
210.710 USD
GILD
0.470
(0.62%)
76.510 USD
I
INCY
-0.680
(-1.05%)
64.390 USD
MRK
0.680
(0.60%)
113.800 USD
PFE
0.115
(0.38%)
30.650 USD
REGN
13.14
(1.22%)
1,091.19 USD
SNY
-0.090
(-0.17%)
51.700 USD
S
SRPT
1.650
(1.16%)
144.000 USD
VRTX
9.75
(1.97%)
505.40 USD
الأخبار المقالات

العنوان: DBV Technologies SA

القطاع: Healthcare
الصناعة: Biotechnology
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.